Europe Antibody-Drug Conjugates Market - Forecasts from 2019 to 2024

September 2019 | 75 pages | ID: EB6AC3281863EN
Knowledge Sourcing Intelligence LLP

Abstracts

The Europe antibody-drug conjugates (ADCs) market is expected to grow at a CAGR of 23.87% to reach a market size of USD2,421.585 million by the end of 2024. The market for antibody-drug conjugates is poised to grow at a rapid pace in the European region with the growing innovations in biotechnology leading to the formation of highly potent pharmaceutical drugs in the forecast period and in the coming years. Also, several companies based in this region are working on the development of highly potent ADCs for the cure of haematological and non-haematological malignancies. Furthermore, a high health expenditure of the European countries is further providing an opportunity for the market to grow in the forecast period with growing concern towards finding an effective cure for cancer patients in this region and at the global level. Moreover, the ability of ADCs to identify and eliminate the disease-associated cells is further gearing the growth of the development of ADCs with the growing incidences of cancer in this region.

The Europe antibody-drug conjugates market – Forecasts from 2019 to 2024 is an exhaustive study which aims to present the key market trends through various chapters focusing on different aspects of the market. The study provides a detailed market overview through the market dynamics sections which detail key market, drivers, restraints, and opportunities in the current market. The report analyzes key opportunity regional markets, and the current technology penetration through lifecycle analysis. The report also analyzes the market through comprehensive market segmentation by the target, by indication, and by country.

The Europe antibody-drug conjugates market on segmented based on target, indication, and country. Based on target the market has been segmented into CD 30, CD 22, and HER 2. By indication, the market is segmented into haematologic malignancies and non-haematologic malignancies.

Country-wise analysis has been provided with detailed analysis and forecast for the period 2018 to 2024, taking 2018 as the base year. The regional market has been broken down into the UK, Germany, France, and others. A thorough analysis and forecast have been done along with the prevailing market trends and opportunities which each of these countries presents for the manufacturers.

Major players in the Europe antibody-drug conjugates market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last year. The company profiles section details the business overview, financial performance for the past three years, key products and services being offered along with the recent developments of these important players in the Europe antibody-drug conjugates market.

Segmentation

The Europe antibody-drug conjugates market has been analyzed through the following segments:

• By Target
• CD 30
• CD 22
• HER 2
• By Indication
• Haematologic Malignancies
• Non-Haematologic Malignancies
• By Country
• United Kingdom
• Germany
• France
• Others

Contents

1. INTRODUCTION

1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness

5. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET BY TARGET

5.1. CD
5.2. CD
5.3. HER

6. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET BY INDICATION

6.1. Haematologic Malignancies
6.2. Non-Haematologic Malignancies

7. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET BY COUNTRY

7.1. United Kingdom
7.2. Germany
7.3. France
7.4. Others

8. COMPETITIVE INTELLIGENCE

8.1. Market Positioning Matrix and Ranking
8.2. Recent Investments and Deals
8.3. Strategies of Key Players

9. COMPANY PROFILES

9.1. Takeda Pharmaceutical Company Limited
9.2. F. Hoffmann-La Roche Ltd.
9.3. Pfizer Inc.
9.4. Synthon Holding B.V.
9.5. Immunomedics GmbH
9.6. Biotest AG
9.7. Astellas Pharma Inc.
9.8. Seattle Genetics, Inc.